Su­per­nus gets a (tem­po­rary) boost as AD­HD drug clears PhI­Ib hur­dle

Rockville, MD-based Su­per­nus re­port­ed pos­i­tive mid-stage da­ta for one of two top ex­per­i­men­tal drugs in the pipeline. The biotech says that three dos­es of SPN-812 — rang­ing from 200 mg to 400 mg a day — hand­i­ly beat out a place­bo in treat­ing AD­HD. But de­spite an ini­tial jump in the stock price, shares quick­ly slid south Tues­day morn­ing.

Us­ing the AD­HD Rat­ing Scale-IV, in­ves­ti­ga­tors tracked base­line score changes of -19.0, -18.6 and -18.4 for the three dos­es. That com­pares fa­vor­ably with the 10.5-point drop for a place­bo, hit­ting the pri­ma­ry end­point in the study. A 100 mg dose failed to mea­sure up, though.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.